A BILL 
To amend the Medicare IVIG Access and Strengthening 
Medicare and Repaying Taxpayers Act of 2012 to extend 
the Medicare Patient IVIG Access Demonstration 
Project. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Continuing Access to 
4
In-Home IVIG Act’’. 
5
23:27 Aug 17, 2020
H7839
2 
•HR 7839 IH
SEC. 2. EXTENSION OF MEDICARE PATIENT IVIG ACCESS 
1
DEMONSTRATION PROJECT. 
2
(a) EXTENSION
OF DEMONSTRATION PROJECT.— 
3
Section 101(b) of the Medicare IVIG Access and Strength-
4
ening Medicare and Repaying Taxpayers Act of 2012 (42 
5
U.S.C. 13951 note) is amended— 
6
(1) by striking paragraph (1) and inserting the 
7
following: 
8
‘‘(1) DURATION.—Beginning not later than one 
9
year after the date of enactment of this Act, the 
10
Secretary shall conduct the demonstration project 
11
for a period of 3 years and, subject to the avail-
12
ability of funds under subsection (g), the period be-
13
ginning on October 1, 2017, and ending on Decem-
14
ber 31, 2022.’’; and 
15
(2) in paragraph (2)— 
16
(A) by striking ‘‘4,000’’ and inserting 
17
‘‘6,500’’; and 
18
(B) by striking ‘‘2020’’ and inserting 
19
‘‘2022’’. 
20
(b) UPDATED EVALUATION AND REPORT.—Section 
21
101(f) is amended— 
22
(1) by redesignating paragraph (2) as para-
23
graph (3); and 
24
(2) by inserting after paragraph (1) the fol-
25
lowing new paragraph: 
26
23:27 Aug 17, 2020
H7839
3 
•HR 7839 IH
‘‘(2) UPDATED
EVALUATION
AND
REPORT.— 
1
Not later than one year after the date of the enact-
2
ment of the Continuing Access to In-Home IVIG 
3
Act, the Secretary shall submit to Congress an up-
4
dated report that contains the following: 
5
‘‘(A) The total number of beneficiaries en-
6
rolled in the demonstration project during the 
7
updated report period. 
8
‘‘(B) The total number of claims submitted 
9
for services during the updated report period, 
10
disaggregated by month. 
11
‘‘(C) An analysis of the impact of the dem-
12
onstration on beneficiary access to the in-home 
13
administration of intravenous immune globin, 
14
including the impact on beneficiary health and 
15
well-being. 
16
‘‘(D) An analysis of the impact of in-home 
17
administration of intravenous immune globin on 
18
overall costs to Medicare, including the cost dif-
19
ferential between in-home administration of in-
20
travenous immune globin and administration of 
21
intravenous immune globin in a healthcare fa-
22
cility. 
23
‘‘(E) A survey of providers and enrolled 
24
beneficiaries that participated in the demonstra-
25
23:27 Aug 17, 2020
H7839
4 
•HR 7839 IH
tion project that identifies barriers to accessing 
1
services, including reimbursement for items and 
2
services. 
3
‘‘(F) Recommendations to Congress on the 
4
appropriateness of establishing a permanent 
5
bundled services payment for the in-home ad-
6
ministration of intravenous immune globin for 
7
Medicare beneficiaries.’’. 
8
(c) DEFINITION OF UPDATED REPORT PERIOD.— 
9
Section 101(h) is amended by adding at the end the fol-
10
lowing new paragraph: 
11
‘‘(4) UPDATED
REPORT
PERIOD.—The term 
12
‘updated report period’ means the period beginning 
13
on October 1, 2014, and ending on September 30, 
14
2020.’’. 
15
Æ 
23:27 Aug 17, 2020
H7839
